| A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia K Tzelepis, H Koike-Yusa, E De Braekeleer, Y Li, E Metzakopian, ... Cell reports 17 (4), 1193-1205, 2016 | 635 | 2016 |
| JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo P Gallipoli, A Cook, S Rhodes, L Hopcroft, H Wheadon, AD Whetton, ... Blood, The Journal of the American Society of Hematology 124 (9), 1492-1501, 2014 | 161 | 2014 |
| Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition P Gallipoli, G Giotopoulos, K Tzelepis, ASH Costa, S Vohra, ... Blood, The Journal of the American Society of Hematology 131 (15), 1639-1653, 2018 | 148 | 2018 |
| Bone marrow mesenchymal stem cells support acute myeloid leukemia bioenergetics and enhance antioxidant defense and escape from chemotherapy D Forte, M García-Fernández, A Sanchez-Aguilera, V Stavropoulou, ... Cell metabolism 32 (5), 829-843. e9, 2020 | 147 | 2020 |
| Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition MT Scott, K Korfi, P Saffrey, LEM Hopcroft, R Kinstrie, F Pellicano, ... Cancer discovery 6 (11), 1248-1257, 2016 | 121 | 2016 |
| targeting Primitive chronic Myeloid leukemia cells by effective inhibition of a New AHi-1–Bcr-ABl–JAK2 complex M Chen, P Gallipoli, D DeGeer, I Sloma, DL Forrest, M Chan, D Lai, ... Journal of the National Cancer Institute 105 (6), 405-423, 2013 | 110 | 2013 |
| Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation P Gallipoli, F Pellicano, H Morrison, K Laidlaw, EK Allan, R Bhatia, ... Blood, The Journal of the American Society of Hematology 122 (19), 3335-3339, 2013 | 104 | 2013 |
| Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML F Basheer, G Giotopoulos, E Meduri, H Yun, M Mazan, D Sasca, ... Journal of Experimental Medicine 216 (4), 966-981, 2019 | 102 | 2019 |
| The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia G Giotopoulos, WI Chan, SJ Horton, D Ruau, P Gallipoli, A Fowler, ... Oncogene 35 (3), 279-289, 2016 | 88 | 2016 |
| Thrombosis and hemostatic abnormalities in hematological malignancies R Colombo, P Gallipoli, R Castelli Clinical Lymphoma Myeloma and Leukemia 14 (6), 441-450, 2014 | 86 | 2014 |
| CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression A Tarafdar, LEM Hopcroft, P Gallipoli, F Pellicano, J Cassels, A Hair, ... Blood, The Journal of the American Society of Hematology 129 (2), 199-208, 2017 | 77 | 2017 |
| Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors SJ Horton, G Giotopoulos, H Yun, S Vohra, O Sheppard, ... Nature cell biology 19 (9), 1093-1104, 2017 | 69 | 2017 |
| SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4 K Tzelepis, E De Braekeleer, D Aspris, I Barbieri, MS Vijayabaskar, ... Nature communications 9 (1), 5378, 2018 | 65 | 2018 |
| Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia P Gallipoli, G Giotopoulos, BJP Huntly Therapeutic advances in hematology 6 (3), 103-119, 2015 | 65 | 2015 |
| A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease GA Horne, J Stobo, C Kelly, A Mukhopadhyay, AL Latif, J Dixon-Hughes, ... Leukemia 34 (7), 1775-1786, 2020 | 55 | 2020 |
| Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies D Sasca, H Yun, G Giotopoulos, J Szybinski, T Evan, NK Wilson, ... Blood, The Journal of the American Society of Hematology 134 (24), 2195-2208, 2019 | 47 | 2019 |
| Targeted therapy in haematological malignancies A Hamilton, P Gallipoli, E Nicholson, TL Holyoake The Journal of Pathology: A Journal of the Pathological Society of Great …, 2010 | 47 | 2010 |
| A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression G Giotopoulos, L van der Weyden, H Osaki, AG Rust, P Gallipoli, E Meduri, ... Journal of Experimental Medicine 212 (10), 1551-1569, 2015 | 45 | 2015 |
| Hurdles toward a cure for CML: the CML stem cell P Gallipoli, SA Abraham, TL Holyoake Hematology/Oncology Clinics 25 (5), 951-966, 2011 | 36 | 2011 |
| Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function R Castelli, GL Deliliers, R Colombo, G Moreo, P Gallipoli, G Pantaleo Annals of hematology 93, 1523-1529, 2014 | 33 | 2014 |
